Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients - Test2 - elhamkhani - TriplyDB

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

http://www.wikidata.org/entity/Q34141845

about

Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1 Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study.Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.Antenatal atazanavir: a retrospective analysis of pregnancies exposed to atazanavir.Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review.Pharmacologic boosting of atazanavir in maintenance HIV-1 therapy: the COREYA propensity-score adjusted study Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state Tenofovir disoproxil fumarate for the treatment of HIV infection.Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.HIV and HAART-Associated Dyslipidemia Atazanavir pharmacokinetics with and without tenofovir during pregnancy Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents.Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients Atazanavir: the advent of a new generation of more convenient protease inhibitors.Emerging anti-HIV drugs.Review of atazanavir: a novel HIV protease inhibitor.Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions.Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors.Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy Atazanavir: simplicity and convenience in different scenarios.Drug interactions between proton pump inhibitors and antiretroviral drugs.Heme oxygenase-1-derived bilirubin counteracts HIV protease inhibitor-mediated endothelial cell dysfunction Predictors of the change in bilirubin levels over twelve weeks of treatment with atazanavir Lack of a significant drug interaction between raltegravir and tenofovir.Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.

P2860

Q28286926-43095B0D-3CE6-476C-A51B-005932BED688 Q31050092-0B401BD4-2AF9-45BD-8B97-2D8631B6C58C Q33348311-7BBA62FD-BA7C-4F73-B3EE-B823DC5F7B1D Q33760652-E9EAE9F2-638F-48CB-98AE-429710E0ECD0 Q34309475-C300DD60-8B40-43DD-AB05-45EAA63A4458 Q34310482-AD7AED1B-77FC-4D54-8266-79A93372D99B Q34405008-7052B0A4-8CAC-4129-926A-2C2F4C4A3A76 Q34477917-C24F1002-10E0-4734-8E42-1D020ED9E4AC Q34495619-DB8127C2-5D5E-4CEE-AE25-1E77EF5C1A36 Q34510726-4864CC08-D284-4E92-B5A8-D599DC9BBC88 Q34569309-051D86E9-0413-4B13-8574-710FD8724B0F Q34776414-C6622CB9-BBFA-4607-BD30-40920FE2CE4A Q35020217-9E66E97F-D1A1-498E-900E-02A36C1F3B13 Q35074548-B3D43DBD-AC35-4776-87B4-41DBFBFECFEB Q35079510-0EB52A46-E127-4723-A29B-B9AF0DE45577 Q35127808-2983D98E-3005-4004-9D8B-807CCB1250EC Q35168318-4AEAB0CC-F140-475C-9EFE-EB57EE62AAD5 Q35191539-5731D006-7028-483A-B272-9471215026B4 Q35224956-13F53112-E5C2-45F5-9C4E-6338FF576E64 Q35758975-27739A96-3FFD-4201-85D5-3739B36AB46B Q35826795-25916D69-FF7F-4525-9C89-EED4A7CFA875 Q35826931-D73C83A2-2B7F-4215-9518-0FA3C85F2329 Q36070100-3596E4D7-A351-4F1D-8216-867113141139 Q36150601-77790404-F172-48DF-9D19-212D78ED2880 Q36222006-0E55853C-539C-41B9-8A7D-DCA9EF55A77F Q36342389-93DC520B-0B44-446C-83AA-D068CC10ECD1 Q36376533-10EE70FB-EDCE-4E84-8C95-348BECF4D74F Q36425083-170BBD56-5AC3-4F26-A673-8A2254567CDF Q36429743-5A241B7E-4B20-4DAF-BFD9-91CE434D8C54 Q36558253-8EFE75EE-2F08-46C3-9F93-508762989608 Q36591913-4A6FCE89-BDB9-4549-A682-3300B35E913F Q36628549-7FCC6D1C-C395-4C65-837A-D54E9647BB63 Q36675895-2F9F0EB5-5498-40C6-A212-665E15CC48F1 Q36763067-F07F618F-6EB2-4F12-880A-26172D0126CF Q36765802-3696AE49-33D8-416D-8895-D4DF1B6B5661 Q36788409-53D63FE9-C9EB-484C-9726-322461BE7627 Q36835027-3DF7FA28-6014-47EC-864C-AAA751251FD4 Q36858737-3E9608BC-6F5E-464A-9FFF-64B3A0C4B051 Q36870935-1E0E4AFF-B2B2-41BB-A21A-FB55E21E8423 Q36876279-D92B084B-80F3-4397-9A9D-920222DADDBD

P2860

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

http://www.wikidata.org/entity/Q34141845

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Interactions between atazanavi ...... ciency virus-infected patients

@ast

Interactions between atazanavi ...... ciency virus-infected patients

@en

Interactions between atazanavi ...... ciency virus-infected patients

@nl

type

label

Interactions between atazanavi ...... ciency virus-infected patients

@ast

Interactions between atazanavi ...... ciency virus-infected patients

@en

Interactions between atazanavi ...... ciency virus-infected patients

@nl

prefLabel

Interactions between atazanavi ...... ciency virus-infected patients

@ast

Interactions between atazanavi ...... ciency virus-infected patients

@en

Interactions between atazanavi ...... ciency virus-infected patients

@nl

P1433

Q34141845-7EC340D5-C5DD-4714-A933-13D5DB982BFA

P1476

Q34141845-435CDE3A-8F09-4EDA-AD75-92F4509CCCD9

P2093

Q34141845-5D7F3586-D691-450E-8E2C-8359A1839C49

Q34141845-75C55CA4-2375-40A7-A7BA-F888D3296F95

Q34141845-7661CB54-1852-4B34-A314-33208183505F

Q34141845-88F7D9CB-39D0-4AC6-A838-D5C4AB0E7753

Q34141845-8911272C-4AD6-4B64-81E9-39519D26D92B

Q34141845-9332F4C7-3CA1-4D4D-BA79-1B3A069FC183

Q34141845-CB7DA916-7AF1-4A0E-BB43-E7785016F078

Q34141845-F3F3D657-E34C-47EA-94C7-5E41B11D74A9

P2860

Q34141845-3C3BFD30-707D-438E-9173-E85EBFE04F2A

Q34141845-6AFB347D-7AAE-41EF-81B5-D14A8819207B

Q34141845-8DF906DA-7C92-4C7B-BCBF-140A8BF407EF

Q34141845-9AE842C3-47E0-4F90-9C52-60084752C675

Q34141845-B1D5D042-BC62-4D7B-9A20-5CB80CDCCED7

Q34141845-B574B2EF-AF6B-4001-A0D7-34E630B8B89D

Q34141845-C5725370-230A-41BB-8D7D-C757009B5173

Q34141845-CAF61A5C-B334-40EE-A7CA-BB75F6585C07

Q34141845-E9B1321A-28B7-465E-BCA6-FCD2B69D9241

Q34141845-EBD7F656-62E7-46E5-BFD7-6B4101C39DFA

P304

Q34141845-14782165-922B-41D8-A4EA-26C320913DDB

P31

Q34141845-23C1368E-4779-495E-B2D3-14566BC6A957

P356

Q34141845-F822C841-DBA1-4144-BAC0-310E6074F3D2

P407

Q34141845-7D8061D5-CB54-49D8-8256-D8DFBC259F1C

P433

Q34141845-4431DDA4-2890-4FFD-A786-E1796DD8659B

P478

Q34141845-5C1EEC56-5A1D-4221-886E-DEFD2CA564C0

P50

Q34141845-F11FDBCF-3C4E-4A87-B6CA-A386249BB9F4

P577

Q34141845-8A949224-F520-4CA7-96C7-31CD9DF6A3B3

P698

Q34141845-88A60860-DD54-4D30-B627-7D2C4D5C2667

P921

Q34141845-5E1CACF3-ED4A-4A63-A87F-6177D0686828

P932

Q34141845-09200818-6A9F-48D2-BEC3-AF601DCCC0F7

P356

AAC.48.6.2091-2096.2004

P1433

Antimicrobial Agents and Chemotherapy

P1476

Interactions between atazanavi ...... ciency virus-infected patients

@en

P2093

Anne-Marie Taburet

http://www.w3.org/2001/XMLSchema#string

Christophe Piketty

http://www.w3.org/2001/XMLSchema#string

Corine Chazallon

http://www.w3.org/2001/XMLSchema#string

Isabelle Vincent

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Aboulker

http://www.w3.org/2001/XMLSchema#string

Laurence Gérard

http://www.w3.org/2001/XMLSchema#string

Pierre-Marie Girard

http://www.w3.org/2001/XMLSchema#string

Vincent Calvez

http://www.w3.org/2001/XMLSchema#string

P2860

In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.

Principles and practice of HIV-protease inhibitor pharmacoenhancement.

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

Role of P-glycoprotein in pharmacokinetics: clinical implications.

A review of low-dose ritonavir in protease inhibitor combination therapy.

Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures.

Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatography-tandem mass spectrometry following automated solid-phase extraction.

The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.

P304

2091-2096

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.48.6.2091-2096.2004

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P50

François Clavel

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15155205

http://www.w3.org/2001/XMLSchema#string

P921

P932

415627

http://www.w3.org/2001/XMLSchema#string